These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25585954)

  • 1. Quality and safety requirements for sustainable phage therapy products.
    Pirnay JP; Blasdel BG; Bretaudeau L; Buckling A; Chanishvili N; Clark JR; Corte-Real S; Debarbieux L; Dublanchet A; De Vos D; Gabard J; Garcia M; Goderdzishvili M; Górski A; Hardcastle J; Huys I; Kutter E; Lavigne R; Merabishvili M; Olchawa E; Parikka KJ; Patey O; Pouilot F; Resch G; Rohde C; Scheres J; Skurnik M; Vaneechoutte M; Van Parys L; Verbeken G; Zizi M; Van den Eede G
    Pharm Res; 2015 Jul; 32(7):2173-9. PubMed ID: 25585954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European regulatory aspects of phage therapy: magistral phage preparations.
    Verbeken G; Pirnay JP
    Curr Opin Virol; 2022 Feb; 52():24-29. PubMed ID: 34801778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phage choice, isolation, and preparation for phage therapy.
    Gill JJ; Hyman P
    Curr Pharm Biotechnol; 2010 Jan; 11(1):2-14. PubMed ID: 20214604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is needed for phage therapy to become a reality in Western medicine?
    Brüssow H
    Virology; 2012 Dec; 434(2):138-42. PubMed ID: 23059181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phage cocktails and the future of phage therapy.
    Chan BK; Abedon ST; Loc-Carrillo C
    Future Microbiol; 2013 Jun; 8(6):769-83. PubMed ID: 23701332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.
    Verbeken G; Huys I; De Vos D; De Coninck A; Roseeuw D; Kets E; Vanderkelen A; Draye JP; Rose T; Jennes S; Ceulemans C; Pirnay JP
    FEMS Microbiol Lett; 2016 Feb; 363(4):. PubMed ID: 26678555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biofilm control with natural and genetically-modified phages.
    Motlagh AM; Bhattacharjee AS; Goel R
    World J Microbiol Biotechnol; 2016 Apr; 32(4):67. PubMed ID: 26931607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameliorating the antimicrobial resistance crisis: phage therapy.
    Saha D; Mukherjee R
    IUBMB Life; 2019 Jul; 71(7):781-790. PubMed ID: 30674079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolutionary Rationale for Phages as Complements of Antibiotics.
    Torres-Barceló C; Hochberg ME
    Trends Microbiol; 2016 Apr; 24(4):249-256. PubMed ID: 26786863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of phage therapy via the intravenous route.
    Speck P; Smithyman A
    FEMS Microbiol Lett; 2016 Feb; 363(3):. PubMed ID: 26691737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages.
    Cisek AA; Dąbrowska I; Gregorczyk KP; Wyżewski Z
    Curr Microbiol; 2017 Feb; 74(2):277-283. PubMed ID: 27896482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical aspects of phage therapy.
    Międzybrodzki R; Borysowski J; Weber-Dąbrowska B; Fortuna W; Letkiewicz S; Szufnarowski K; Pawełczyk Z; Rogóż P; Kłak M; Wojtasik E; Górski A
    Adv Virus Res; 2012; 83():73-121. PubMed ID: 22748809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational models of populations of bacteria and lytic phage.
    Krysiak-Baltyn K; Martin GJ; Stickland AD; Scales PJ; Gras SL
    Crit Rev Microbiol; 2016 Nov; 42(6):942-68. PubMed ID: 26828960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial bioagents based on principles of bacteriophage biology: an overview.
    Knoll BM; Mylonakis E
    Clin Infect Dis; 2014 Feb; 58(4):528-34. PubMed ID: 24270166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phages and their potential to modulate the microbiome and immunity.
    Federici S; Nobs SP; Elinav E
    Cell Mol Immunol; 2021 Apr; 18(4):889-904. PubMed ID: 32901128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis.
    Golkar Z; Bagasra O; Pace DG
    J Infect Dev Ctries; 2014 Feb; 8(2):129-36. PubMed ID: 24518621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phages & antibiotic resistance: are the most abundant entities on earth ready for a comeback?
    Hill C; Mills S; Ross RP
    Future Microbiol; 2018 May; 13():711-726. PubMed ID: 29792526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The perspectives of the application of phage therapy in chronic bacterial prostatitis.
    Letkiewicz S; Międzybrodzki R; Kłak M; Jończyk E; Weber-Dąbrowska B; Górski A
    FEMS Immunol Med Microbiol; 2010 Nov; 60(2):99-112. PubMed ID: 20698884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possibilities of bacteriophage therapy].
    Skurnik M; Kiljunen S
    Duodecim; 2016; 132(8):712-9. PubMed ID: 27244930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.